DDInter1607 DDInter667
Ritonavir is an HIV protease inhibitor that interferes with the reproductive cycle of HIV. Although it was initially developed as an independent antiviral agent, it has been shown to possess advantageous properties in combination regimens with low-dose ritonavir and other protease inhibitors. It is now more commonly used as a booster of other protease inhibitors and is available in both liquid formulations and as capsules. While ritonavir is not an active antiviral agent against hepatitis C virus (HCV) infection, it is added in combination therapies indicated for the treatment of HCV infections as a booster. Ritonavir is a potent CYP3A inhibitor that increases peak and trough plasma drug concentrations of other protease inhibitors such as and overall drug exposure. American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) guidelines recommend ritonavir-boosted combination therapies as first-line therapy for HCV Genotype 1a/b and
Erlotinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that is used in the treatment of non-small cell lung cancer, pancreatic cancer and several other types of cancer. It is typically marketed under the trade name Tarceva. Erlotinib binds to the epidermal growth factor receptor (EGFR) tyrosine kinase in a reversible fashion at the adenosine triphosphate (ATP) binding site of the receptor. Recent studies demonstrate that erlotinib is also a potent inhibitor of JAK2V617F, which is a mutant form of tyrosine kinase JAK2 found in most patients with polycythemia vera (PV) and a substantial proportion of patients with idiopathic myelofibrosis or essential thrombocythemia. This finding introduces the potential use of erlotinib in the treatment of JAK2V617F-positive PV and other myeloproliferative disorders.
Ritonavir {u} (Compound) binds {v} (Gene) CYP1A2
CYP1A2 {u} (Gene) is bound by {v} (Compound) Erlotinib
Ritonavir {u} (Compound) causes {v} (Side Effect) Drug interaction
Drug interaction {u} (Side Effect) is caused by {v} (Compound) Erlotinib
Ritonavir {u} (Compound) resembles {v} (Compound) Atazanavir
Atazanavir {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Erlotinib
Ritonavir {u} (Compound) binds {v} (Gene) CYP1A2
CYP1A2 {u} (Gene) is bound by {v} (Compound) Modafinil
Modafinil {u} may cause a minor interaction that can limit clinical effects when taken with {v} Erlotinib
Ritonavir {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) is bound by {v} (Compound) Gefitinib
Gefitinib {u} (Compound) resembles {v} (Compound) Erlotinib
Ritonavir {u} (Compound) binds {v} (Gene) CYP2C8
CYP2C8 {u} (Gene) is bound by {v} (Compound) Verapamil
Verapamil {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Erlotinib
Ritonavir {u} (Compound) binds {v} (Gene) ABCG2
ABCG2 {u} (Gene) is bound by {v} (Compound) Vandetanib
Vandetanib {u} (Compound) resembles {v} (Compound) Erlotinib
Ritonavir {u} (Compound) causes {v} (Side Effect) Drug interaction
Drug interaction {u} (Side Effect) is caused by {v} (Compound) Gefitinib
Gefitinib {u} (Compound) resembles {v} (Compound) Erlotinib
Ritonavir {u} (Compound) causes {v} (Side Effect) Connective tissue disorder
Connective tissue disorder {u} (Side Effect) is caused by {v} (Compound) Modafinil
Modafinil {u} may cause a minor interaction that can limit clinical effects when taken with {v} Erlotinib
Ritonavir {u} (Compound) causes {v} (Side Effect) Interstitial lung disease
Interstitial lung disease {u} (Side Effect) is caused by {v} (Compound) Vandetanib
Vandetanib {u} (Compound) resembles {v} (Compound) Erlotinib
Ritonavir (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Erlotinib (Compound)
Ritonavir (Compound) causes Drug interaction (Side Effect) and Drug interaction (Side Effect) is caused by Erlotinib (Compound)
Ritonavir (Compound) resembles Atazanavir (Compound) and Atazanavir may cause a moderate interaction that could exacerbate diseases when taken with Erlotinib
Ritonavir (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Modafinil (Compound) and Modafinil may cause a minor interaction that can limit clinical effects when taken with Erlotinib
Ritonavir (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Gefitinib (Compound) and Gefitinib (Compound) resembles Erlotinib (Compound)
Ritonavir (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Verapamil (Compound) and Verapamil may cause a moderate interaction that could exacerbate diseases when taken with Erlotinib
Ritonavir (Compound) binds ABCG2 (Gene) and ABCG2 (Gene) is bound by Vandetanib (Compound) and Vandetanib (Compound) resembles Erlotinib (Compound)
Ritonavir (Compound) causes Drug interaction (Side Effect) and Drug interaction (Side Effect) is caused by Gefitinib (Compound) and Gefitinib (Compound) resembles Erlotinib (Compound)
Ritonavir (Compound) causes Connective tissue disorder (Side Effect) and Connective tissue disorder (Side Effect) is caused by Modafinil (Compound) and Modafinil may cause a minor interaction that can limit clinical effects when taken with Erlotinib
Ritonavir (Compound) causes Interstitial lung disease (Side Effect) and Interstitial lung disease (Side Effect) is caused by Vandetanib (Compound) and Vandetanib (Compound) resembles Erlotinib (Compound)